安科生物(300009) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥484,825,921.75, representing a 53.76% increase compared to ¥315,318,856.84 in the same period last year[2]. - The net profit attributable to shareholders for Q1 2021 was ¥125,584,242.74, up 54.30% from ¥81,391,603.65 in the previous year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥118,014,351.64, reflecting a 61.62% increase from ¥73,019,797.86 year-on-year[2]. - The net cash flow from operating activities for Q1 2021 was ¥83,549,693.39, an increase of 47.10% compared to ¥56,796,395.54 in the same period last year[2]. - The basic earnings per share for Q1 2021 was ¥0.09, a 50.00% increase from ¥0.06 in the same period last year[2]. - The diluted earnings per share for Q1 2021 was also ¥0.09, reflecting a 50.00% increase compared to ¥0.06 in the previous year[2]. - The weighted average return on equity for Q1 2021 was 4.33%, up from 3.05% in the same period last year[2]. - Operating profit for the quarter was 147.17 million CNY, up 52.26% from the previous year[10]. - The company reported a gross profit margin of approximately 30.9% for Q1 2021, compared to 29.1% in Q1 2020[36]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,687,412,245.13, which is a 5.21% increase from ¥3,504,878,857.95 at the end of the previous year[2]. - The total liabilities increased to CNY 631,913,951.58 from CNY 576,290,707.68, representing an increase of about 9.7%[32]. - The total equity reached CNY 3,055,498,293.55, up from CNY 2,928,588,150.27, marking an increase of about 4.3%[33]. - The total amount of accounts payable to employees decreased by 32.40% compared to the beginning of the year, as the company paid out previously accrued salaries and bonuses[9]. - Current liabilities rose to CNY 508,721,649.30 from CNY 472,543,970.44, representing an increase of approximately 7.5%[32]. Research and Development - The company's R&D expenses increased by 70.98% year-on-year, indicating a strong commitment to advancing research activities[9]. - The company plans to enhance new product R&D management and improve efficiency through talent acquisition and industry-academia collaboration[13]. - The company reported a total R&D expense of CNY 32,684,673.43, a significant increase of 70.9% compared to CNY 19,116,198.27 in the previous year[37]. Market and Product Development - The company reported a 64.41% increase in revenue from its main product, recombinant human growth hormone, contributing to overall sales growth[10]. - The company submitted a marketing authorization application for recombinant human growth hormone for the treatment of idiopathic short stature, which was accepted by the National Medical Products Administration[12]. - The company is expanding its market presence and brand influence while actively promoting new product development and technological innovation[12]. Financial Management and Investments - The company’s investment income increased by 49.67% year-on-year, attributed to higher returns from bank wealth management products[9]. - The total amount raised from the non-public offering in March 2019 was approximately RMB 682 million, with a net amount of RMB 663 million after deducting related expenses[16]. - The total amount of raised funds is 66,348.8 million, with 2,659.8 million invested in the current quarter, totaling 38,214.43 million invested to date[22]. Risks and Challenges - The company faces risks from new drug development not meeting expectations, which could adversely affect profitability and growth potential[12]. - The company is addressing potential goodwill impairment risks from acquisitions, which could negatively impact future performance if actual profits do not meet projections[14]. - The company has recognized the impact of COVID-19 on production and sales, and is implementing multi-channel strategies to mitigate adverse effects[17]. Cash Flow and Financing Activities - The cash flow from operating activities amounted to CNY 83,549,693.39, an increase of 47.1% compared to CNY 56,796,395.54 in the previous year[44]. - The cash flow from investing activities showed a net outflow of CNY 118,597,751.35, compared to a net outflow of CNY 185,687,344.67 in the previous year[44]. - The company’s cash flow from financing activities resulted in a net inflow of CNY 621,720.87, down from CNY 1,634,234.75 in the previous year[45]. Corporate Structure and Subsidiaries - The company completed the transfer of 100% equity of Guangdong Anke South Biological Technology Co., Ltd. to its wholly-owned subsidiary, enhancing its corporate structure[18]. - The company’s subsidiary Hefei Hanke Maibo Biotechnology Co., Ltd. raised RMB 30 million in a capital increase to support its development needs[18]. Miscellaneous - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[21]. - There are no significant changes in the feasibility of investment projects during the reporting period[26]. - The company has not experienced any major changes in expected benefits from its projects during the reporting period[24].